NCT06418776View on ClinicalTrials.gov

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

PHASE3RecruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2029

Conditions
Refractory Acute Myeloid LeukemiaEarly Relapses of Acute Myeloid Leukemia
Interventions
OTHER

Intensive therapy

Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)

OTHER

Low intensity therapy

Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)

Trial Locations (1)

125167

RECRUITING

National Research Center for Hematology, Moscow

All Listed Sponsors
collaborator

St. Petersburg State Pavlov Medical University

OTHER

collaborator

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

OTHER

lead

National Research Center for Hematology, Russia

NETWORK